Lv31
400 积分 2021-07-05 加入
Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure
4小时前
已完结
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
1个月前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
1个月前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy
1个月前
已完结
Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
1个月前
已完结
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
2个月前
已关闭
Consensus on the lung cancer management after third-generation EGFR-TKI resistance
2个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
2个月前
已完结
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies
3个月前
已完结
皖公网安备34019202002308
